Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and FLT3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of autoimmune disease or cancer.

Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Abstract: The present invention relates to pharmaceutical formulations for heterodimeric Fc-fused proteins which are advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are dosage regimens for such heterodimeric Fc-fused proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.

Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.

Abstract: This disclosure relates to pharmaceutical formulations for multi-specific binding proteins having an epidermal growth factor receptor 2 (ErbB2 or HER2)-binding scFv, an NKG2D-binding Fab, and an antibody Fc domain. Also provided are dosage regimens for such multi-specific binding proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.

Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting DLL3 (Delta-like 3) on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.

Abstract: Multi-specific binding proteins that bind the NKG2D receptor, CD 16, and a tumor-associated antigen on tumor cells, or an antigen on myeloid-derived suppressor cells or tumor-associated macrophages are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Abstract: The invention provides improvements on single-chain variable fragment (scFv) antibodies, multi-specific binding proteins, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.

Abstract: A front plane laminate useful in the manufacture of electro-optic displays comprises, in order, a light-transmissive electrically-conductive layer, a layer of an electro-optic medium in electrical contact with the electrically-conductive layer, an adhesive layer and a release sheet. This front plane laminate can be prepared as a continuous web, cut to size, the release sheet removed and the laminate laminated to a backplane to form a display. Methods for providing conductive vias through the electro-optic medium and for testing the front plane laminate are also described.

Abstract: A front plane laminate (see U.S. Pat. No. 6,982,178) is produced by forming a sub-assembly comprising a lamination adhesive layer and an electro-optic layer, forming an aperture through the sub-assembly, and securing a light-transmissive electrode layer to the sub-assembly so that the electrode layer extends across the aperture. Alternatively, formation of the aperture is omitted, and the electrode layer has a tab portion extending beyond the edges of the lamination adhesive and electro-optic layers. When a front plane laminate is secured to a backplane to form an electro-optic display, a stiffening layer may be attached to either part to increase its stiffness, then removed after the lamination. An electro-optic display or front plane laminate may use an adhesive layer comprising separate layers of cross-linked and non-cross-linked adhesive.

Abstract: A front plane laminate useful in the manufacture of electro-optic displays comprises, in order, a light-transmissive electrically-conductive layer, a layer of an electro-optic medium in electrical contact with the electrically-conductive layer, an adhesive layer and a release sheet. This front plane laminate can be prepared as a continuous web, cut to size, the release sheet removed and the laminate laminated to a backplane to form a display. Methods for providing conductive vias through the electro-optic medium and for testing the front plane laminate are also described.

Abstract: An electro-optic display (100) comprising a backplane (102), a layer (112) of electro-optic material and a protective layer (128) capable of absorbing ultra-violet radiation and disposed on the opposed side of the layer (112) of electro-optic material from the backplane (102), is provided with an edge seal (130). The protective layer (128) extends beyond the layer (112) of electro-optic material, thus leaving a peripheral gap between the protective layer (128) and the backplane (102). To form the edge seal (130) an uncured edge sealing material curable by radiation transmitted by the protective layer (128) is placed in the gap and cured by transmitting radiation through the protective layer (128).

Abstract: The invention relates to electro-optic displays and methods for driving such displays. The invention provides (i) electrochromic displays with solid charge transport layers; (ii) apparatus and methods for improving the contrast and reducing the cost of electrochromic displays; (iii) apparatus and methods for sealing electrochromic displays from the outside environment and preventing ingress of contaminants into such a display; and (iv) methods for adjusting the driving of electro-optic displays to allow for environmental and operating parameters.

Abstract: A front plane laminate useful in the manufacture of electro-optic displays comprises, in order, a light-transmissive electrically-conductive layer, a layer of an electro-optic medium in electrical contact with the electrically-conductive layer, an adhesive layer and a release sheet. This front plane laminate can be prepared as a continuous web, cut to size, the release sheet removed and the laminate laminated to a backplane to form a display. Methods for providing conductive vias through the electro-optic medium and for testing the front plane laminate are also described.

Abstract: Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Abstract: An encapsulated electrophoretic display is produced by laminating an electrophoretic medium, comprising a plurality of discrete droplets (104) in a polymeric binder (106?), each droplet (104) comprising a plurality of electrophoretic particles dispersed in a suspending fluid, to a backplane (110) having at least one electrode at a temperature such that the polymeric binder (106?) flows and secures the electrophoretic medium to the backplane (110).

Abstract: A method for sensing the state of an electrophoretic display includes the steps of applying an electrical signal to a display element, measuring an electrical response for the display element, and deducing the state of the display element from the measured electrical response. Also, the parameters of the display materials are determined using the encapsulated electrophoretic display media as a sensor, either alone or in conjunction with other sensors.